Pages that link to "Q45753683"

The following pages link to Statistical methods for assessing differential vaccine protection against human immunodeficiency virus types (Q45753683):

Displaying 17 items.

• Sieve analysis in HIV-1 vaccine efficacy trials (Q26851376) (← links)
• Sieve analysis: methods for assessing from vaccine trial data how vaccine efficacy varies with genotypic and phenotypic pathogen variation (Q30626592) (← links)
• Analysis of Two-sample Censored Data Using a Semiparametric Mixture Model. (Q33630386) (← links)
• HIV-1 envelope proteins and V1/V2 domain scaffolds with mannose-5 to improve the magnitude and quality of protective antibody responses to HIV-1 (Q33947008) (← links)
• Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2 (Q34298408) (← links)
• Inferences on relative failure rates in stratified mark-specific proportional hazards models with missing marks, with application to HIV vaccine efficacy trials (Q35026809) (← links)
• Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trial (Q35043417) (← links)
• Estimation of vaccine efficacy in a repeated measures study under heterogeneity of exposure or susceptibility to infection (Q35581701) (← links)
• SieveSifter: a web-based tool for visualizing the sieve analyses of HIV-1 vaccine efficacy trials (Q36335509) (← links)
• Case-only method for cause-specific hazards models with application to assessing differential vaccine efficacy by viral and host genetics (Q37390044) (← links)
• Improved estimation of the cumulative incidence of rare outcomes. (Q38697365) (← links)
• Leaky vaccines protect highly exposed recipients at a lower rate: implications for vaccine efficacy estimation and sieve analysis (Q39935700) (← links)
• Sieve analysis using the number of infecting pathogens. (Q46241496) (← links)
• Interpretability and robustness of sieve analysis models for assessing HIV strain variations in vaccine efficacy. (Q52927884) (← links)
• Hypothesis tests for stratified mark-specific proportional hazards models with missing covariates, with application to HIV vaccine efficacy trials. (Q54265267) (← links)
• Estimation of the efficacy of live, attenuated influenza vaccine from a two-year, multi-center vaccine trial: implications for influenza epidemic control (Q73502933) (← links)
• Epitope-based sieve analysis of Plasmodium falciparum sequences from a FMP2.1/AS02A vaccine trial is consistent with differential vaccine efficacy against immunologically relevant AMA1 variants (Q96639316) (← links)